E-viri
PDF
Recenzirano
Odprti dostop
-
Norrby, Maria; Vesikari, Timo; Lindqvist, Lars; Maeurer, Markus; Ahmed, Raija; Mahdavifar, Shahnaz; Bennett, Sean; McClain, J. Bruce; Shepherd, Barbara M; Li, Daner; Hokey, David A; Kromann, Ingrid; Hoff, Søren T; Andersen, Peter; de Visser, Adriëtte W; Joosten, Simone A; Ottenhoff, Tom H.M; Andersson, Jan; Brighenti, Susanna
Vaccine, 03/2017, Letnik: 35, Številka: 12Journal Article
Highlights • H4:IC31 vaccination was well tolerated with an acceptable safety profile. • H4:IC31 vaccination elicited persistent antigen-specific CD4+ T cell responses. • H4:IC31 triggered T cell expansion, IFNγ production and multifunctional Th1 cells. • Optimal antigen-adjuvant doses were 5, 15, or 50 μg of H4 plus 500 nmol of IC31.
